Key regulator of fat cell differentiation identified

NewsGuard 100/100 Score

New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).

Adipose tissue plays an important role in controlling the balance of insulin in our bodies as well as energy production and consumption. White adipose tissue is a storage depot for excess energy in the form of fat.
Excessive adipocyte (fat cell) size and/or number is a hallmark of obesity, which is a major risk factor for developing type-II diabetes, cardiovascular disease and hypertension.

Professor Ericsson and his team have demonstrated that the protein Fbxw7 regulates the cascade of events that control the development of fat cells. They found that when Fbxw7 was inactive, the development of fat cells was enhanced. In fact, in the case of mouse precursor or immature fat cells, the inactivation of this protein alone was enough to convert them to mature fat cells. The team also demonstrated that Fbxw7 blocks the development of fat cells because it tags other proteins in the regulatory cascade for destruction.

Commenting on the results, Professor Ericsson said; 'The picture we have built of the role of Fbxw7 in energy and lipid metabolism suggests that it is a key regulator of this process. As such, it may impact on two very important health problems, type-II diabetes and obesity'.

In the future, the group would like to determine exactly how Fbxw7 regulates adipocyte differentiation, and identify the factors and signals that control the amount of this protein in fat cells. It will also be important to determine if the levels of Fbxw7 are changed during the development of obesity.

In Ireland, an estimated 200,000 people are suffering from type-II diabetes and it is anticipated that this will rise by 37% in the coming years. This places an enormous burden on the national healthcare budget as people are treated for the disease and its complications.

http://www.pnas.org/content/early/2010/05/12/0913367107.abstract

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery